Immuron Ltd ADR (IMRN)

$1.62 +0.09 (5.88%)
Market Cap 10.63M
Revenue (ttm) 4.72M
Net Income (ttm) -3.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.61%
Debt to Equity Ratio 0.00
Volume 97,700
Avg Vol 202,188
Day's Range N/A - N/A
Shares Out 6.95M
Stochastic %K 75%
Beta 0.70
Analysts Strong Buy
Price Target $5.00

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3 Carlton South, Carlton, Australia
Baseball89
Baseball89 Nov. 19 at 5:35 PM
$IMRN Need Alerts!!!!Get it running
0 · Reply
ALDX_Bull
ALDX_Bull Nov. 14 at 11:51 AM
$IMRN some overlooked aspects of this company. 1. production scales via dairy infrastructure - not expensive bioreactors. 2. the 3 current indications have a market opp >500M per year. 3. All of them can be sold BEFORE FDA approval. 4. Readout from government study can get yellow book listing which would immediately and dramatically expand the market for Travelan as well as get worldwide military orders (prior to FDA approval).
0 · Reply
Baseball89
Baseball89 Nov. 14 at 1:01 AM
$IMRN this should be over $30 by now
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 13 at 5:31 PM
$IMRN Government open again-- tick tok
0 · Reply
Boom_Badabing
Boom_Badabing Nov. 11 at 5:01 PM
$IMRN So why am getting emails of this Clinical Trial Update stock when I've never heard of them - so is this a good investment?
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 7 at 3:33 PM
$IMRN Australians are willing to pay 1.8 and they supported 1.75 significantly.
0 · Reply
aletz
aletz Nov. 6 at 9:33 PM
$IMRN https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #8 on the list
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 6 at 5:36 PM
$IMRN Immuron Limited boosts R&D funding to expand its oral immunotherapy pipeline and strengthen IMRN stock’s biotech outlook in 2025. https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/
0 · Reply
StockfatherOG
StockfatherOG Nov. 6 at 3:43 PM
$IMRN considering U.S. Investors are willing to invest $13M in them just shows they are undervalued. The private placement is worth more than their market cap. Huge news likely by the end of the year.
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 6 at 1:35 PM
$IMRN ATM sold the equivalent of 200k shares at $1.96 yesteday
0 · Reply
Latest News on IMRN
Immuron IMM-529 IND approved by FDA

Nov 5, 2025, 6:00 AM EST - 16 days ago

Immuron IMM-529 IND approved by FDA

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Oct 17, 2025, 11:07 AM EDT - 4 weeks ago

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Immuron Q1 FY26 YoY growth

Oct 13, 2025, 6:00 AM EDT - 5 weeks ago

Immuron Q1 FY26 YoY growth

Immuron Submits IMM-529 IND to FDA

Oct 8, 2025, 6:00 AM EDT - 6 weeks ago

Immuron Submits IMM-529 IND to FDA

Immuron Letter to Shareholders – Projects Update

Oct 2, 2025, 6:00 AM EDT - 7 weeks ago

Immuron Letter to Shareholders – Projects Update

Immuron partners with InvestorHub

Aug 26, 2025, 10:29 PM EDT - 3 months ago

Immuron partners with InvestorHub

Immuron - FY25 global sales exceed projection, up 49% on prior year

Jul 17, 2025, 6:00 AM EDT - 4 months ago

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron Letter to Shareholders: Projects Update

May 30, 2025, 6:00 AM EDT - 6 months ago

Immuron Letter to Shareholders: Projects Update

Immuron Travelan® highest sales in history

Apr 10, 2025, 6:00 PM EDT - 8 months ago

Immuron Travelan® highest sales in history

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Mar 5, 2025, 6:00 AM EST - 9 months ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron Travelan® continued strong sales growth

Jan 17, 2025, 6:00 AM EST - 11 months ago

Immuron Travelan® continued strong sales growth

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Jan 15, 2025, 6:00 AM EST - 11 months ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Immuron Announces Travelan® Clinical Trial Update

Jan 14, 2025, 6:00 AM EST - 11 months ago

Immuron Announces Travelan® Clinical Trial Update

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Dec 2, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Nov 21, 2024, 6:33 PM EST - 1 year ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Nov 18, 2024, 8:30 AM EST - 1 year ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Oct 16, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Oct 4, 2024, 6:30 AM EDT - 1 year ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Sep 19, 2024, 9:42 AM EDT - 1 year ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Sep 5, 2024, 11:54 AM EDT - 1 year ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS GOVX

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Aug 16, 2024, 6:00 AM EDT - 1 year ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Aug 15, 2024, 6:14 PM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Aug 7, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron Board Changes

Immuron CEO Steven Lydeamore to present at Peak Sky High

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

Immuron Limited to Present at the Emerging Growth Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Immuron Limited to Present at the Emerging Growth Conference

Immuron Director Resignation

May 3, 2024, 6:00 AM EDT - 1 year ago

Immuron Director Resignation

Immuron to host Live Virtual Event

Apr 15, 2024, 6:00 AM EDT - 1 year ago

Immuron to host Live Virtual Event

Immuron Travelan® sales continued strong growth

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Immuron Travelan® sales continued strong growth

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Mar 7, 2024, 6:00 AM EST - 1 year ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Immuron Presentation Australian Biologics Festival 2024

Feb 21, 2024, 6:00 AM EST - 1 year ago

Immuron Presentation Australian Biologics Festival 2024

Immuron achieves record Travelan® sales

Feb 13, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record Travelan® sales

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Feb 8, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Immuron achieves record half yearly Travelan® sales

Jan 16, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record half yearly Travelan® sales

Immuron Clinical Trials Update

Dec 22, 2023, 6:00 AM EST - 2 years ago

Immuron Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Dec 4, 2023, 6:00 AM EST - 2 years ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Nov 13, 2023, 6:00 PM EST - 2 years ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 30, 2023, 7:21 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 18, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron achieves record quarterly Travelan® sales

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record quarterly Travelan® sales

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 18, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Immuron achieves record monthly Travelan® sales

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Immuron to present at the Military Health System Research Symposium

Aug 14, 2023, 6:00 AM EDT - 2 years ago

Immuron to present at the Military Health System Research Symposium

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Jul 25, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Immuron CEO, Steven Lydeamore to present at Bioshares

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at Bioshares

Immuron Business Update - Ateria Health launches Juvia™ in Australia

Jul 11, 2023, 6:00 AM EDT - 2 years ago

Immuron Business Update - Ateria Health launches Juvia™ in Australia

Immuron FY23 Sales increase 136% on FY22 Sales

Jul 5, 2023, 6:00 AM EDT - 2 years ago

Immuron FY23 Sales increase 136% on FY22 Sales

Baseball89
Baseball89 Nov. 19 at 5:35 PM
$IMRN Need Alerts!!!!Get it running
0 · Reply
ALDX_Bull
ALDX_Bull Nov. 14 at 11:51 AM
$IMRN some overlooked aspects of this company. 1. production scales via dairy infrastructure - not expensive bioreactors. 2. the 3 current indications have a market opp >500M per year. 3. All of them can be sold BEFORE FDA approval. 4. Readout from government study can get yellow book listing which would immediately and dramatically expand the market for Travelan as well as get worldwide military orders (prior to FDA approval).
0 · Reply
Baseball89
Baseball89 Nov. 14 at 1:01 AM
$IMRN this should be over $30 by now
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 13 at 5:31 PM
$IMRN Government open again-- tick tok
0 · Reply
Boom_Badabing
Boom_Badabing Nov. 11 at 5:01 PM
$IMRN So why am getting emails of this Clinical Trial Update stock when I've never heard of them - so is this a good investment?
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 7 at 3:33 PM
$IMRN Australians are willing to pay 1.8 and they supported 1.75 significantly.
0 · Reply
aletz
aletz Nov. 6 at 9:33 PM
$IMRN https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #8 on the list
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 6 at 5:36 PM
$IMRN Immuron Limited boosts R&D funding to expand its oral immunotherapy pipeline and strengthen IMRN stock’s biotech outlook in 2025. https://biotechhealthx.com/biotech-news/immuron-imrn-raises-8-5m-for-biotech-expansion/
0 · Reply
StockfatherOG
StockfatherOG Nov. 6 at 3:43 PM
$IMRN considering U.S. Investors are willing to invest $13M in them just shows they are undervalued. The private placement is worth more than their market cap. Huge news likely by the end of the year.
1 · Reply
ALDX_Bull
ALDX_Bull Nov. 6 at 1:35 PM
$IMRN ATM sold the equivalent of 200k shares at $1.96 yesteday
0 · Reply
StockfatherOG
StockfatherOG Nov. 5 at 7:38 PM
$IMRN they are for sure diluting. Wait for it to settle and play it for the news coming this month.
1 · Reply
Show_me_the_fkin_money
Show_me_the_fkin_money Nov. 5 at 3:44 PM
$IMRN I Caught The News (For Once) Within 10 Seconds Of Release. Then Almost Immediately -£500 LOL How Does That Work? Would Have Been Way Better Off Buying In Hours After News.
2 · Reply
bjhbj
bjhbj Nov. 5 at 2:15 PM
$IMRN Expect a strong recovery.
0 · Reply
ALDX_Bull
ALDX_Bull Nov. 5 at 1:54 PM
$IMRN on a positive note -- the p2 trial is 60 people and only in Australia. I'm sure based on government/university support they will get this recruited in lightning speed. Of course, DoD field study is the real catalyst-- but today's PR was certainly positive.
1 · Reply
elmono
elmono Nov. 5 at 1:36 PM
$IMRN HC Wain ATM working in overdrive 😂😂😂
0 · Reply
doublenickels55
doublenickels55 Nov. 5 at 1:28 PM
$IMRN I mean it's a little weird that a drug get FDA approval and the stock drop almost 20%.
0 · Reply
TheNavigator
TheNavigator Nov. 5 at 1:08 PM
$IMRN Strong catalyst setup, good entry point, expecting continuation to the upside
0 · Reply
Tnsi
Tnsi Nov. 5 at 12:14 PM
$IMRN I mean I expected it to drop after the algo-spike, but this just broke a massive support The last time it was at this level was 2023. Of course this is just pre-market, still very Disproportionate action compared to the ASX:IMC , this will have to go back up to around 1.80 by the end of the week. The divergence between NSDQ and ASX prices doesn't make any sense.
2 · Reply
doublenickels55
doublenickels55 Nov. 5 at 12:12 PM
$IMRN Now setting new one year lows - this is a good entry point if you're tracking the movement. At about 9 AM this should push up to around $2.20...
0 · Reply
ALDX_Bull
ALDX_Bull Nov. 5 at 11:57 AM
$IMRN traders who bought the headline don't hold. they sell and move on to the next thing. pendulum swings both ways-- in a few days it will be back at equilibrium. Government likely to reopen this week and end of Nov will come soon.
0 · Reply
doublenickels55
doublenickels55 Nov. 5 at 11:53 AM
$IMRN year to date low almost.
0 · Reply
Gjur
Gjur Nov. 5 at 11:44 AM
$IMRN scam, most probably old offering
0 · Reply